Citations

Clear

390 citation(s) found for "Loftus, E".

Predictors of Durability of Radiological Response in Patients With Small Bowel Crohn’s Disease
Deepak, Parakkal , Fidler, Jeff L. , Barlow, John M. , Sheedy, Shannon P. , Kolbe, Amy B. , Harmsen, William S. , Therneau, Terry M. , Becker, Brenda D., Loftus, Edward V. , Bruining, David H. , Loftus, Edward V , Deepak, Parakkal , Fletcher, Joel G. , Fidler, Jeff L. , Hansel, Stephanie L.

Mayo Clinic

Inflammatory Bowel Diseases | April 13, 2018 | Volume: 24 | Issue: 8 | Pages: 1815-1825

10.1093/ibd/izy074 | PMID 29668921 Get It

Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis
Mouchli, Mohamad, Singh, Siddharth , Boardman, Lisa, Bruining, David H. , Rosen, Charles B. , Poterucha, John J., Watt, Kymberly D. , Kane, Sunanda V. , Raffals, Laura E. , Loftus, Edward V. , Mouchli, Mohamad A, Hasan, Bashar , Loftus, Edward V , Boardman, Lisa, Lightner, Amy L. , Heimbach, Julie K. , Hasan, Bashar

Mayo Clinic

Inflammatory Bowel Diseases | March 7, 2018 | Volume: 24 | Issue: 5 | Pages: 1074-1081

10.1093/ibd/izx096 | PMID 29522202 Get It

Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study
Mathis, Kellie L. , Tse, Chung Sang , Pembérton, John H., Shen, Bo , Kochhar, Gursimran , Singh, Amandeep , Dulai, Parambir S. , Eisenstein, Samuel , Sandborn, William J. , Parry, Lisa, Stringfield, Sarah , Hudesman, David , Remzi, Feza H. , Loftus, Edward V. , Tse, C S , Loftus, Edward V , Lightner, Amy L.

Mayo Clinic

Inflammatory Bowel Diseases | March 2, 2018 | Volume: 24 | Issue: 4 | Pages: 871-876

10.1093/ibd/izx076 | PMID 29509927 Get It

A102 TOLERABILITY OF USTEKINUMAB IN INDUCTION AND MAINTENANCE FOR THE TREATMENT OF CROHN’S DISEASE
Jacobstein, D, Gasink, Christopher , Sloan, S , Feagan, Brian G. , Loftus, Edward V. , Sattin, Bernie D. , Jacobstein, D, Colombel, Jean‐Frédéric

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | March 1, 2018 | Volume: 1 | Issue: suppl_2 | Pages: 153-154

10.1093/jcag/gwy009.102 Get It

Incidence and cost analysis of hospital admission and 30‐day readmission among patients with cirrhosis
Chirapongsathorn, Sakkarin , Krittanawong, Chayakrit , Pendegraft, Richard S., Mara, Kristin C. , Visscher, Sue L. , Loftus, Conor G., Shah, Vijay H. , Talwalkar, Jayant A., Kamath, Patrick S. , Borah, Bijan J. , Shah, Vijay H , Mara, Kristin C , Enders, Felicity

Mayo Clinic

Hepatology Communications | January 18, 2018 | Volume: 2 | Issue: 2 | Pages: 188-198

10.1002/hep4.1137 | PMID 29404526 Get It

We examined risks for first hospitalization and the rate, risk factors, costs, and 1‐year outcome of 30‐day readmission among patients admitted for complications of cirrhosis. Data were retrospectively analyzed for adult patients with cirrhosis residing in Minnesota, Iowa, or Wisconsin and admitted from 2010 through 2013 at both campuses of the Mayo Clinic Hospital in Rochester, MN. Readmission was captured at the two hospitals as well as at community hospitals in the tristate area within the Mayo Clinic Health System. The incidence of hospitalization for complications of cirrhosis was 100/100,000 population, with increasing age and male sex being the strongest risks for hospitalization. For the 2,048 hospitalized study patients, the overall 30‐day readmission rate was 32%; 498 (24.3%) patients were readmitted to Mayo Clinic hospitals and 157 (7.7%) to community hospitals, mainly for complications of portal hypertension (52%) and infections (30%). Readmission could not be predicted accurately. There were 146 deaths during readmission and an additional 105 deaths up to 1 year of follow‐up (50.4% total mortality). Annual postindex hospitalization costs for those with a 30‐day readmission were substantially higher ($73,252) than those readmitted beyond 30 days ($62,053) or those not readmitted ($5,719). At 1‐year follow‐up, only 20.4% of patients readmitted within 30 days were at home. In conclusion, patients with cirrhosis have high rates of hospitalization, especially among men over 65 years, and of unscheduled 30‐day readmission. Readmission cannot be accurately predicted. Postindex hospitalization costs are high; nationally, the annual costs are estimated to be more than $4.45 billion. Only 20% of patients readmitted within 30 days are home at 1 year. (Hepatology Communications 2018;2:188–198)
Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity
Morris, Marc, Stewart, Samuel A. , Heisler, Courtney , Sandborn, William J. , Loftus, Edward V. , Zello, Gordon A. , Fowler, Sharyle , Jones, Jennifer , Loftus, Edward V

Mayo Clinic

Inflammatory Bowel Diseases | January 18, 2018 | Volume: 24 | Issue: 2 | Pages: 277-285

10.1093/ibd/izx018 | PMID 29361090 Get It

Striated muscle-specific β1D-integrin and FAK are involved in cardiac myocyte hypertrophic response pathway
Pham, Can G., Harpf, Alice E., Keller, Rebecca S., Shai, Shaw‐Yung, Loftus, Joseph C. , Zemljic‐Harpf, Alice E. , Vu, Hoa T., Ross, Robert S.

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | December 22, 2017 | Volume: 279 | Issue: 6 | Pages: H2916-H2926

10.1152/ajpheart.2000.279.6.h2916 | PMID 11087248 Get It

Alterations in the extracellular matrix occur during the cardiac hypertrophic process. Because integrins mediate cell-matrix adhesion and β1D-integrin (β1D) is expressed exclusively in cardiac and skeletal muscle, we hypothesized that β1D and focal adhesion kinase (FAK), a proximal integrin-signaling molecule, are involved in cardiac growth. With the use of cultured ventricular myocytes and myocardial tissue, we found the following: 1) β1D protein expression was upregulated perinatally; 2) α1-adrenergic stimulation of cardiac myocytes increased β1D protein levels 350% and altered its cellular distribution; 3) adenovirally mediated overexpression of β1D stimulated cellular reorganization, increased cell size by 250%, and induced molecular markers of the hypertrophic response; and 4) overexpression of free β1D cytoplasmic domains inhibited α1-adrenergic cellular organization and atrial natriuretic factor (ANF) expression. Additionally, FAK was linked to the hypertrophic response as follows: 1) coimmunoprecipitation of β1D and FAK was detected; 2) FAK overexpression induced ANF-luciferase; 3) rapid and sustained phosphorylation of FAK was induced by α1-adrenergic stimulation; and 4) blunting of the α1-adrenergically modulated hypertrophic response was caused by FAK mutants, which alter Grb2 or Src binding, as well as by FAK-related nonkinase, a dominant interfering FAK mutant. We conclude that β1D and FAK are both components of the hypertrophic response pathway of cardiac myocytes.
Postoperative outcomes in vedolizumab‐treated Crohn's disease patients undergoing major abdominal operations
Lightner, Amy L. , McKenna, Nicholas P. , Raffals, Laura E. , Loftus, Edward V. , Mathis, Kellie L. , Lightner, A L , Loftus, Edward V , Tse, Chung Sang , McKenna, Nicholas P

Mayo Clinic

Alimentary Pharmacology & Therapeutics | December 18, 2017 | Volume: 47 | Issue: 5 | Pages: 573-580

10.1111/apt.14459 | PMID 29250800 Get It

SummaryBackgroundUp to 80% of patients with Crohn's disease require an abdominal operation in their lifetime. As the use of vedolizumab is increasing for the treatment of Crohn's disease, it is important to understand its potential association with post‐operative complications.AimWe sought to compare 30‐day postoperative infectious complication rate among vedolizumab‐treated Crohn's disease patients vs those who had received TNFα inhibitors or no biologic therapy.MethodsA retrospective review of all Crohn's disease patients who received vedolizumab within 12 weeks of a major abdominal or pelvic operation was performed. Two control cohorts consisted of Crohn's disease patients treated with TNFα inhibitors or no biologic therapy.ResultsOne hundred Crohn's disease patients received vedolizumab within 12 weeks of an abdominal operation. Vedolizumab‐treated patients underwent an equivalent rate of laparoscopic surgery (P = .25), had fewer anastomoses performed (P = .0002), and had equally frequent diversion in the setting of anastomoses (P = .47). Thirty‐two vedolizumab‐treated patients experienced postoperative infectious complications (32%), 26 of which were surgical site infections (26%). The vedolizumab‐treated group experienced no difference in nonsurgical site infections (6% vs 5% anti‐TNFα and 2% nonbiologic; P = .34), but significantly higher rates of surgical site infections (26% vs 8% and 11%; P < .001). On univariate and multivariate analysis, exposure to vedolizumab remained a significant predictor of postoperative surgical site infection (P < .001 and P = .002).ConclusionsTwenty‐six per cent of Crohn's disease patients who received vedolizumab within 12 weeks prior to a major abdominal operation experienced a 30‐day postoperative surgical site infection, significantly higher than that of patients receiving TNFα inhibitors or no biologic therapy. Vedolizumab within 12 weeks of surgery remained a predictor of 30‐day postoperative surgical site infection on multivariable analysis. While vedolizumab‐treated Crohn's disease patients may be a sicker cohort of patients, it is important to consider these findings with regard to preoperative counselling, operative timing and primary closure of wounds.